Abstracts tagged "Antibodies"

Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Devon Charlton¹, Maureen Laffoon², Thomas A. Medsger Jr.³ and Robyn T. Domsic⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Fang Shen¹, Jennifer F. Nemeth², Brian Jones¹, Ann Cai¹, Shannon Hitchcock³, Thai Dinh², Ravi Malaviya¹ and Tatiana Ort¹, ¹Immunology, Janssen R&D, Spring House, PA, ²Janssen Biotech, Janssen R&D, Spring House, PA, ³Immunology, Janssen R&D, Springhouse, PA
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 1666 • 2017 ACR/ARHP Annual Meeting
Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations
Yann Becker¹, Renee Claude Loignon¹, Genevieve Marcoux¹, Anne-Sophie Julien², Imene Melki¹, Lihi Eder³, Eric Wagner¹, Martin Pelletier¹, Marie-Josee Hebert⁴, Clemence Belleannee¹, Joyce Rauch⁵, Melanie Dieude⁴, Paul R. Fortin⁶ and Eric Boilard¹, ¹CHU de Quebec and Universite Laval, Quebec City, QC, Canada, ²CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴CHUM and Universite de Montreal, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada
- Background/Purpose: Eukaryotic cells contain organelles called mitochondria that govern energy supply and control of cell death. Whereas damaged organs or activated cells can extrude…
Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
Abstract Number: 2682 • 2016 ACR/ARHP Annual Meeting
How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project
Pilar Brito-Zerón^1,2,3, Nihan Acar-Denizli⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Raphaele Seror⁷, Elke Theander⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori^14,15, Gabriela Hernandez-Molina¹⁶, Aike A. Kruize¹⁷, Valeria Valim¹⁸, Marika Kvarnström¹⁹, Damien Sene²⁰, Roberto Gerli²¹, Sonja Praprotnik²², David A. Isenberg²³, Roser Solans²⁴, Maureen Rischmueller²⁵, Seung-Ki Kwok²⁶, Gunnel Nordmark²⁷, Yasunori Suzuki²⁸, Roberto Giacomelli²⁹, Valerie Devauchelle-Pensec³⁰, Michele Bombardieri³¹, Benedikt Hofauer³², Hendrika Bootsma³³, Johan G. Brun³⁴, Guadalupe Fraile³⁵, Steven E. Carsons³⁶, Tamer Gheita³⁷, Jacques Morel³⁸, Cristina F. Vollenweider³⁹, Fabiola Atzeni⁴⁰, Soledad Retamozo⁴¹, Ildike-Fanny Horvath⁵, Kathy Sivils⁶, Thomas Mandl^42,43, Pulukool Sandhya¹², Salvatore De Vita⁴⁴, Jorge Sánchez-Guerrero⁴⁵, Eefje van der Heijden¹⁷, Virginia Moça Trevisano⁴⁶, Marie Wahren-Herlenius¹⁹, Xavier Mariette⁷, Manuel Ramos-Casals^3,47,48 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), ¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, ⁸Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ⁹Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ¹⁴Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁵Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁷Department of Rheumatology & Clinical Immunology, Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁸Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ¹⁹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, ²¹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ²²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁵Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, ²⁶[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁸Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, ²⁹Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, ³⁰Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³¹Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, ³²Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, ³³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³⁴Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ³⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ³⁶Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, ³⁷Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ³⁸Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, ³⁹Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴⁰IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, ⁴¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ⁴²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ⁴³Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, ⁴⁴Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ⁴⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁴⁶Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, ⁴⁷Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, ⁴⁸Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To analyse the main characteristics of patients with primary Sjögren syndrome (SjS) with focal lymphocytic sialadenitis (FLS) unrelated to the presence of circulating anti-Ro/La…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 2687 • 2016 ACR/ARHP Annual Meeting
Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies
Isabel Martinez Cordellat¹, Francisco Miguel Ortiz-Sanjuán¹, Jose Ivorra Cortes¹, Luis Gonzalez Puig¹, Inmaculada Chalmeta Verdejo¹, Irene Calabuig Sais², Elena Grau Garcia^1,3, Carlos Feced Olmos¹, Eztizen Labrador Sanchez¹, Karla Arevalo Ruales¹, Rosa Negueroles Albuixech¹, Jorge Fragio Gil¹, Jose Luis Valero Sanz¹, Cristina Alcañiz Escandell^1,3, Carmen Najera Herranz¹, Gema Poveda Marin^1,3 and Jose Andres Roman Ivorra^1,2,3, ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Universidad Católica de Valencia, Valencia, Spain, ³IIS La Fe, Valencia, Spain
Background/Purpose: anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality. We included 162 patients with positive anti-SSA/Ro and/or…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis
Sen Hee Tay¹, Anna-Marie Fairhurst² and Anselm Mak¹, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…
Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Robert W. Georgantas III¹, Melanie Ruzek², Justin Wade Davis¹, Feng Hong¹, Elizabeth Asque¹, Kenneth Idler¹, Heikki T. Mansikka¹, Benoit Guerette¹ and Jeffrey F. Waring¹, ¹AbbVie Inc., North Chicago, IL, ²Immunology Discovery, AbbVie, Worcester, MA
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
Abstract Number: 2841 • 2016 ACR/ARHP Annual Meeting
Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
Luis F. Perez-Garcia¹, Irving Omar Estevez-Garcia¹, Mariana Moreno Ramirez¹, Javier Loaiza Felix¹, Ricardo Marquez-Velasco², Pedro Iturralde³, Luis H. Silveira^4,5 and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico
Background/Purpose: Long QT syndrome (LQTS) is characterized by an abnormal QT corrected (QTc) interval prolongation that is associated with increased risk of sudden death. Studies…
Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Mark C. Genovese¹, Michael Weinblatt², Jacob A Aelion³, Heikki T. Mansikka⁴, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Ahmed A. Othman⁴, Amit Khatri⁴, Nasser S. Khan⁴ and Robert J. Padley⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³West Tennessee Research Institute, Jackson, TN, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting
Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups
Caroline Grönwall¹, Uta Hardt¹, Iva Gunnarsson², Gregg J. Silverman³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…